January 25, 2019 11:16 AM ESTUpdated May 26, 08:22 PM

A stem cell therapy preps debut in Japanese market to the dismay of US researchers

Amber Tong

As Japan approves a stem cell treatment for spinal cord injuries in a landmark — if little noticed — decision, experts around the world have voiced concerns …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A stem cell therapy preps debut in Japanese market to the dismay of US researchers

Amber Tong

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

A stem cell ther­a­py preps de­but in Japan­ese mar­ket to the dis­may of US re­searchers

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

A stem cell therapy preps debut in Japanese market to the dismay of US researchers